List view / Grid view
UK biotech commits to scale up of 228Th extraction and a long-term supply agreement to facilitate production of thousands of doses of 212Pb for cancer therapies annually.
The EMA’s human medicines committee also recommended approval of drugs by GSK, Moderna, STADA, Lupin Europe and Cytokinetics.
The $11bn collaboration with the Chinese biopharma company gives Takeda the rights to several next-generation candidates.
The FDA’s latest authorisation makes it the most widely approved of any CD19-directed CAR T therapy in cancer.
Acquisition of the US biotech gives Johnson & Johnson rights to clinical-stage precision treatments for solid tumours.
California site adds to the Swiss pharma company’s operations in Florida and Texas.
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
Merck & Co’s anti-PD-1 immunotherapy showed evidence at ESMO of its ability to prevent cancer recurrence in Merkel cell carcinoma.
Companies’ first-line ambitions for the antibody drug conjugate buoyed by the TROPION-Breast02 clinical trial.
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
The CHMP hands the cancer drug two new recommendations, and the FDA approves its subcutaneous use as Keytruda Qlex.
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
EASYGEN is supported by EU funding andindustry partners that include Fresenius, Charles River, Cellix, Pro-Liance and TQ Therapeutics.
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.
The new appointee has over twenty years of experience in biopharma and extensive senior expertise in oncology.
